Equivalent Medication to Adderall XR 15 mg

Methylphenidate as First-Line Alternative

The American Academy of Child and Adolescent Psychiatry recommends that if there is inadequate response to one stimulant class, switching to the other class is the appropriate next step, with approximately 70% of patients responding to either stimulant class alone, but nearly 90% responding when both classes are tried sequentially 2
Methylphenidate extended-release formulations are the preferred alternative to Adderall XR, with Concerta (OROS-methylphenidate) starting at 27-36 mg once daily, providing 12-hour coverage comparable to Adderall XR 15 mg 1, 2

Lisdexamfetamine (Vyvanse) can be used as an alternative, starting at 30 mg once daily, which is a prodrug formulation that reduces abuse potential while providing once-daily dosing 4, 1

Atomoxetine (Strattera) can be used as a non-stimulant alternative, with a target dose of 60-100 mg daily for adults, and a median time to effect of 3.7 weeks, with full therapeutic effect requiring 6-12 weeks 1
Alpha-2 adrenergic agonists, such as extended-release guanfacine and clonidine, can be used as monotherapy or adjunctive therapy, with an effect size around 0.7, and should be administered in the evening due to somnolence/fatigue as common adverse effects 1, 3

When switching from Adderall XR to methylphenidate, response to one stimulant versus another is idiosyncratic, with approximately 40% responding to both, and 40% responding to only one, and methylphenidate should be started at appropriate initial doses, not direct mg-to-mg conversion 1, 2
Blood pressure and pulse should be monitored at baseline and regularly during treatment, as both stimulant classes cause statistically significant increases, and height and weight should be monitored, as both cause dose-related reductions in growth velocity 1, 2

The American College of Cardiology and other guideline societies recommend screening for contraindications, such as uncontrolled hypertension, symptomatic cardiovascular disease, and within 14 days of MAOI use, before prescribing stimulants 1
Anxiety is NOT a contraindication for stimulant use, but requires careful monitoring, and substance use disorder should be thoroughly screened before prescribing any stimulant, with consideration of formulations with lower abuse potential or non-stimulant alternatives 1, 2